GRD1R Grindeks

Regarding changes in the Management Board of JSC “Grindeks” subsidiary JSC “Kalceks”

Regarding changes in the Management Board of JSC “Grindeks” subsidiary JSC “Kalceks”

As of February 18, the Management Board of JSC “Kalceks”, a subsidiary of “Grindeks”, has been changed – the member of the Management Board Egils Kopstals has been appointed as the new Chairman of the Board of JSC “Kalceks”. Kaspars Kuprevics, the Quality and R&D Director/Qualified person has also joined JSC “Kalceks” Management Board. Juris Hmelnickis, who was the Chairman of the Board of JSC “Kalceks” since 2014 and who on 4 February 2020 was approved by the Supervisory Council of JSC “Grindeks” as the new Chairman of the Board of JSC “Grindeks”, will continue to actively participate in JSC “Kalceks”, performing the duties of a member of the Management Board.

Egils Kopstals has 20 years of experience in JSC “Grindeks” group as he joined JSC “Kalceks” in 2000. Simultaneously with working at JSC “Kalceks” has was also the Head of Investment Department of JSC “Grindeks” from 2007 to 2012 and the Chief Economist from 2012. Since 2018 Egils Kopstals has been working at JSC “Kalceks” only.

Kaspars Kuprevics is the Quality and R&D Director and has been working in the pharmaceutical and chemistry industry since 2006. Kaspars Kuprevics joined JSC “Kalceks” in 2015 as a qualified person. He begun working in JSC “Grindeks” in 2006 as technician in Chromatography Laboratory but gradually extended his career and became the Head of the Quality Control Laboratory.

About JSC “Grindeks”

“Grindeks” is an international pharmaceutical company focused on research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. The Group of “Grindeks” has four subsidiary companies in Latvia, Estonia, and Slovakia as well as representative offices in 11 countries.

“Grindeks” specializes in the heart and cardiovascular, CNS, anti-cancer and gastroenterological medication therapeutic groups. A range of products covers a combination of original products Mildronate® (meldonium*) and Ftorafur®, generics, food supplements and active pharmaceutical ingredients.

*Notice: meldonium is included in the list of substances prohibited in sport.

Further information:

Olga Grisina

Public Relations Specialist, JSC “Grindeks”

Phones: (+371) 67083334, (+371) 29155441

Fax: (+371) 67083505

EN
19/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Grindeks

 PRESS RELEASE

В 2020 году концерн «Гриндекс»  достиг исторически самого стремительно...

В 2020 году концерн «Гриндекс»  достиг исторически самого стремительного оборота и роста прибыли В 2020 году концерн «Гриндекс»  достиг исторически самого стремительного оборота и роста прибыли В 2020 году концерн «Гриндекс» достиг исторически самого стремительного оборота и роста прибыли. Консолидированные, провизорские финансовые данные концерна свидетельствуют о том, что в 2020 году оборот концерна «Гриндекс» достиг 187 млн. евро, что на 45,6 млн. евро или на 32% больше чем в 2019 году. Прибыль концерна в 2020 году составила 19 млн. евро, что на 5,6 млн. евро или на 42% больше чем...

 PRESS RELEASE

In 2020 the “Grindeks” Group has achieved the historically sharpest i...

In 2020 the “Grindeks” Group has achieved the historically sharpest increase in turnover and profit In 2020 the “Grindeks” Group has achieved the historically sharpest increase in turnover and profit In 2020 the “Grindeks” Group has achieved the historically sharpest increase in turnover and profit. The consolidated, preliminary financial data of the Group show that in 2020 the turnover of the “Grindeks” Group reached 187.0 million euro, which is 45.6 million euro or 32% more than in 2019. In 2020 the Group’s profit amounted to 19.0 million euro, which is 5.6 million euro or 42% mor...

 PRESS RELEASE

2020. gadā “Grindeks” koncerns sasniedzis vēsturiski straujāko apgrozī...

2020. gadā “Grindeks” koncerns sasniedzis vēsturiski straujāko apgrozījuma un peļņas kāpumu 2020. gadā “Grindeks” koncerns sasniedzis vēsturiski straujāko apgrozījuma un peļņas kāpumu 2020. gadā “Grindeks” koncerns sasniedzis vēsturiski straujāko apgrozījuma un peļņas kāpumu. Koncerna konsolidētie, provizoriskie finanšu dati liecina, ka 2020. gadā “Grindeks” koncerna apgrozījums sasniedza 187,0 milj. eiro, kas ir par 45,6 milj. eiro vai 32% vairāk nekā 2019. gadā. 2020. gada koncerna peļņa bija 19,0 milj. eiro, kas ir par 5,6 milj. eiro vai par 42% vairāk nekā 2019. gadā.  2020....

 PRESS RELEASE

Andrejs Liberts ievēlēts par AS “Grindeks” valdes locekli

Andrejs Liberts ievēlēts par AS “Grindeks” valdes locekli Andrejs Liberts ievēlēts par AS “Grindeks” valdes locekli AS “Grindeks” informē, ka saskaņā ar AS “Grindeks” padomes lēmumu par valdes locekli AS “Grindeks” valdē ir ievēlēts Andrejs Liberts. A.Liberts ir dzimis 1985. gadā. Farmācijas industrijā A.Liberts sevi ir pierādījis kā spēcīgs biznesa attīstības un pārdošanas profesionālis. Šobrīd savas profesionālās prasmes un pieredzi viņš realizē kā AS “Grindeks” Komercdaļas direktors, atbildot par sekmīgu mārketinga, pārdošanas un loģistikas rezultātu sasniegšanu. Iepriekš...

 PRESS RELEASE

Andrejs Liberts appointed as the member of the board of JSC “Grindeks”

Andrejs Liberts appointed as the member of the board of JSC “Grindeks” Andrejs Liberts appointed as the member of the board of JSC “Grindeks” JSC “Grindeks” informs, that based on decision of JSC “Grindeks” council, Andrejs Liberts has been appointed as the member of JSC “Grindeks” board. A.Liberts was born in 1985, he has proven himself in pharmaceutical industry as a strong business development and sales professional. At the moment, he uses his professional skills and experience as the Commercial Director of JSC “Grindeks”, he is responsible for successful marketing, sales and lo...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch